ATE529435T1 - Agonisten und antagonisten der rezeptoren des insulin und des igf-1 - Google Patents
Agonisten und antagonisten der rezeptoren des insulin und des igf-1Info
- Publication number
- ATE529435T1 ATE529435T1 AT00918510T AT00918510T ATE529435T1 AT E529435 T1 ATE529435 T1 AT E529435T1 AT 00918510 T AT00918510 T AT 00918510T AT 00918510 T AT00918510 T AT 00918510T AT E529435 T1 ATE529435 T1 AT E529435T1
- Authority
- AT
- Austria
- Prior art keywords
- insulin
- agonists
- antagonists
- peptides
- receptors
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 108010001127 Insulin Receptor Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 102000038455 IGF Type 1 Receptor Human genes 0.000 title 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 title 1
- 102000003746 Insulin Receptor Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 2
- 102000004584 Somatomedin Receptors Human genes 0.000 abstract 2
- 108010017622 Somatomedin Receptors Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108010067902 Peptide Library Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001165 hydrophobic group Chemical group 0.000 abstract 1
- 239000000813 peptide hormone Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/008528 WO2001072771A2 (en) | 2000-03-29 | 2000-03-29 | Insulin and igf-1 receptor agonists and antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE529435T1 true ATE529435T1 (de) | 2011-11-15 |
Family
ID=21741219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00918510T ATE529435T1 (de) | 2000-03-29 | 2000-03-29 | Agonisten und antagonisten der rezeptoren des insulin und des igf-1 |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1383793B1 (de) |
JP (1) | JP2004512010A (de) |
AT (1) | ATE529435T1 (de) |
AU (1) | AU2000239309A1 (de) |
CA (1) | CA2402780A1 (de) |
WO (1) | WO2001072771A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
EP1282437B1 (de) | 2000-05-16 | 2008-03-19 | Genentech, Inc. | Behandlung von knorpelerkrankungen |
CA2431033A1 (en) | 2001-02-09 | 2002-08-22 | Genentech, Inc. | Crystallization of igf-1 |
WO2002072780A2 (en) | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
IL164376A0 (en) * | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
CA2484000A1 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
AU2003256299A1 (en) | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
US7511012B2 (en) * | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
EP1670822A2 (de) | 2003-10-03 | 2006-06-21 | Genentech, Inc. | Igf-bindende proteine |
EP1694850B1 (de) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmidsystem zur expression mehrerer gene |
CA2582552A1 (en) * | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
EP2351841A1 (de) | 2005-03-25 | 2011-08-03 | National Research Council of Canada | Verfahren zur Isolation von löslichen Polypeptiden |
CA2650656A1 (en) * | 2005-05-05 | 2007-01-11 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
US7659362B2 (en) * | 2006-05-30 | 2010-02-09 | Academia Sinica | Metal-binding motif compositions and methods |
US20110039779A1 (en) | 2007-04-24 | 2011-02-17 | Soren Ostergaard | Igf-1r binding proteins and antagonists |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
JP2014156401A (ja) * | 2011-05-25 | 2014-08-28 | Hoya Corp | Igf−1r結合性ペプチド |
CN111377773A (zh) * | 2020-04-16 | 2020-07-07 | 山东省现代中药研究院有限公司 | 一种含内生菌的花生用海藻复合微生物有机肥 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963665A (en) * | 1986-01-07 | 1990-10-16 | Washington University | Human preproinsulin-like growth factor I |
US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US6010861A (en) | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
DE4432943A1 (de) * | 1994-09-15 | 1996-03-21 | Radulescu Razvan T Dr Med M D | Numerical Mirror Image Strategy (NUMIS) |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
AU705035B2 (en) * | 1995-06-07 | 1999-05-13 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
RU2078769C1 (ru) * | 1995-08-18 | 1997-05-10 | Научно-исследовательский институт биомедицинской химии РАМН | Пептидный фрагмент, обладающий биологической активностью инсулина |
WO1997007827A1 (en) * | 1995-08-22 | 1997-03-06 | Thomas Jefferson University | Gab1, A Grb2 BINDING PROTEIN, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME |
WO1997046682A2 (en) * | 1996-06-07 | 1997-12-11 | Genetics Institute, Inc. | Polynucleotides from human adult pbmc encoding secreted proteins |
DE69830301T2 (de) * | 1997-01-15 | 2006-02-02 | Telik Inc., South San Francisco | Modulatoren von insulinrezeptor-aktivität |
US6413517B1 (en) * | 1997-01-23 | 2002-07-02 | Epimmune, Inc. | Identification of broadly reactive DR restricted epitopes |
US7020563B1 (en) * | 1997-11-27 | 2006-03-28 | Commonwealth Scientific And Industrial Research Organisation | Method of designing agonists and antagonists to IGF receptor |
CA2317941A1 (en) * | 1998-01-16 | 1999-07-22 | Genzyme Corporation | Adenoviral vectors with modified capsid proteins |
JP2002522029A (ja) * | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
-
2000
- 2000-03-29 AT AT00918510T patent/ATE529435T1/de not_active IP Right Cessation
- 2000-03-29 WO PCT/US2000/008528 patent/WO2001072771A2/en active Application Filing
- 2000-03-29 AU AU2000239309A patent/AU2000239309A1/en not_active Abandoned
- 2000-03-29 EP EP00918510A patent/EP1383793B1/de not_active Expired - Lifetime
- 2000-03-29 CA CA002402780A patent/CA2402780A1/en not_active Abandoned
- 2000-03-29 JP JP2001571702A patent/JP2004512010A/ja active Pending
- 2000-03-29 EP EP10186251A patent/EP2368902A3/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2368902A3 (de) | 2011-12-21 |
JP2004512010A (ja) | 2004-04-22 |
EP2368902A2 (de) | 2011-09-28 |
CA2402780A1 (en) | 2001-10-04 |
EP1383793A2 (de) | 2004-01-28 |
AU2000239309A1 (en) | 2001-10-08 |
EP1383793B1 (de) | 2011-10-19 |
WO2001072771A2 (en) | 2001-10-04 |
WO2001072771A3 (en) | 2003-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE529435T1 (de) | Agonisten und antagonisten der rezeptoren des insulin und des igf-1 | |
WO2003070747A3 (en) | Insulin and igf-1 receptor agonists and antagonists | |
MA31242B1 (fr) | Co-agonistes des recepteurs du glucagon/glp-1 | |
DE60335216D1 (de) | Adiponektin-rezeptor und dafür kodierendes gen | |
DE60126624D1 (de) | Zyklische peptide als agonisten für den melanocortin-4-rezeptor | |
SG149693A1 (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
GB2286398A (en) | Human metabotropic glutamate receptors,nucleic acids encoding same and uses thereof | |
CR9452A (es) | Agentes terapeuticos a base de peptidos de toxinas | |
HK1047755A1 (zh) | 胰島素樣生長因子激動肽的用途 | |
DE69836638D1 (de) | Peptidanaloga abgeleitet vom tumornekrose-faktor-rezeptor | |
DK1355942T3 (da) | GLP-1-fusionsproteiner | |
DK1265605T3 (da) | Farmaceutiske sammensætninger omfattende peptidmimetisk, cyklisk beta-drejningsforbindelse | |
ATE241616T1 (de) | Abgewandelte aminosäureamide als cgrp antagonisten | |
DK1282437T3 (da) | Behandling af brusklidelser | |
IL181311A (en) | Variants of neoblastin polypeptide, dimers, conjugates, and fusion proteins that include them, pharmacological compounds based on them, nucleic acids encoding them, and vectors - expression including said nucleic acids, cells containing said vectors, methods for making and using said polypeptides | |
TW200635919A (en) | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | |
WO2005009358A3 (en) | Conformationally constrained parathyroid hormone (pth) analogs | |
WO2002102839A3 (en) | Novel g-protein coupled receptors and dna sequences thereof | |
ES2129120T3 (es) | Un receptor de celulas t humanas de la familia de receptores acoplados a la proteina g. | |
DE69936638D1 (de) | Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel | |
DE602004027039D1 (de) | Cytokinpolypeptidvarianten | |
DE602004030899D1 (de) | Neues screening-verfahren | |
DE69032096D1 (de) | Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte | |
ATE445159T1 (de) | Neues screening-verfahren | |
Lee et al. | Suppression of Follicle Apoptosis by Pituitary Adenylate Cyclase Activating Peptide in the Rat Ovary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |